Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

VitaNova Life Sciences Corp

CIK 1699709 VNOV·Wholesale Trade · All EDGAR filings ↗

Progression

  1. Finance chief departure 8-K
  2. Accounting standard newly cited 10-K +154d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Accounting standard newly cited Filing comparison

VitaNova Life Sciences Corp cited accounting standard ASU 2016-13 for the first time in this filing series

Credit Losses On May 1, 2024, the Company adopted ASU 2016-13 Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments(ASC 326).
Evidence
Adopted
2016-13
Contexts
Credit Losses On May 1, 2024, the Company adopted ASU 2016-13 Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments(ASC 326).
New standards
2016-13, 2023-06, 2024-03, 2025-01, 2025-04
Prior filed
2025-07-24
Prior form
10-K
Restates existing policy
No
Source
accounting standards update (ASU) reference comparison
Why
The summary of significant accounting policies changed materially from the previous comparable filing.

Source filing ↗ Prior filing ↗

Finance chief departure Filing comparison

VitaNova Life Sciences Corp's Chief Financial Officer departed and a successor was named

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
normal
Source
SEC 8-K item code
Successor named
Yes
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗